JP2015506376A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506376A5
JP2015506376A5 JP2014555805A JP2014555805A JP2015506376A5 JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5 JP 2014555805 A JP2014555805 A JP 2014555805A JP 2014555805 A JP2014555805 A JP 2014555805A JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
patient
cancer
administering
cdk8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506376A (ja
JP6193268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/024515 external-priority patent/WO2013116786A1/en
Publication of JP2015506376A publication Critical patent/JP2015506376A/ja
Publication of JP2015506376A5 publication Critical patent/JP2015506376A5/ja
Application granted granted Critical
Publication of JP6193268B2 publication Critical patent/JP6193268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555805A 2012-02-02 2013-02-01 Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 Expired - Fee Related JP6193268B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US61/594,023 2012-02-02
US201261673419P 2012-07-19 2012-07-19
US61/673,419 2012-07-19
PCT/US2013/024515 WO2013116786A1 (en) 2012-02-02 2013-02-01 Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer

Publications (3)

Publication Number Publication Date
JP2015506376A JP2015506376A (ja) 2015-03-02
JP2015506376A5 true JP2015506376A5 (enExample) 2016-05-19
JP6193268B2 JP6193268B2 (ja) 2017-09-06

Family

ID=47716178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555805A Expired - Fee Related JP6193268B2 (ja) 2012-02-02 2013-02-01 Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用

Country Status (16)

Country Link
US (2) US9321737B2 (enExample)
EP (2) EP2809324B1 (enExample)
JP (1) JP6193268B2 (enExample)
KR (1) KR20150023223A (enExample)
CN (1) CN104363913B (enExample)
AU (1) AU2013214783B2 (enExample)
BR (1) BR112014019052A8 (enExample)
CL (1) CL2014002062A1 (enExample)
CO (1) CO7151516A2 (enExample)
EA (2) EA032429B1 (enExample)
GE (1) GEP201706688B (enExample)
MY (1) MY165446A (enExample)
PH (1) PH12014501862A1 (enExample)
SG (1) SG11201404596UA (enExample)
UA (1) UA117342C2 (enExample)
WO (1) WO2013116786A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI631097B (zh) 2012-07-27 2018-08-01 百健Ma公司 作爲s1p調節劑及/或atx調節劑之化合物
KR20150044952A (ko) * 2012-08-23 2015-04-27 에프. 호프만-라 로슈 아게 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드
JP6310470B2 (ja) 2012-11-01 2018-04-11 ユニバーシティ オブ サウス カロライナ 前立腺がんを処置するための方法
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
JP6529085B2 (ja) * 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
WO2016018511A2 (en) * 2014-06-10 2016-02-04 University Of South Carolina Methods and compositions for treatment of her-positive cancers
EP3233086B1 (en) 2014-12-18 2023-02-15 University of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
KR20180003597A (ko) * 2015-05-08 2018-01-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유도체로의 치료를 위한 환자의 표적화된 선택
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
BR112018008931A8 (pt) 2015-11-03 2019-02-26 Lu License Ab ?compostos para tratamento de distúrbios hipoproliferativos?
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
JP7198489B2 (ja) * 2016-03-23 2023-01-04 国立大学法人 岡山大学 リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用
WO2018027082A1 (en) 2016-08-03 2018-02-08 The Broad Institute, Inc. Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity
JP7142846B2 (ja) * 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性t細胞の製造方法
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
WO2018156858A1 (en) * 2017-02-23 2018-08-30 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
JPWO2018159805A1 (ja) * 2017-03-03 2020-01-09 国立大学法人京都大学 膵前駆細胞の製造方法
JP7152784B2 (ja) * 2017-04-03 2022-10-13 京都薬品工業株式会社 新規サイクリン依存性キナーゼ8及び/又は19阻害剤
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
WO2019055977A1 (en) 2017-09-18 2019-03-21 Chan Zuckerberg Biohub, Inc. METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER
JP7285249B2 (ja) 2017-10-02 2023-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cdk8/cdk19阻害剤としての新規な[1,6]ナフチリジン化合物及び誘導体
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
EP3917523B1 (en) 2019-02-01 2024-09-11 University of South Carolina Bicyclic pyridine compounds for use in treating cancer
CN116391028A (zh) 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
CN116829697A (zh) 2021-02-09 2023-09-29 千纸鹤治疗公司 促熟剂
US20240180921A1 (en) * 2021-03-25 2024-06-06 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
TW202330910A (zh) 2021-09-27 2023-08-01 國立大學法人京都大學 T細胞的製造方法
MX2024006370A (es) 2021-11-24 2024-08-19 Regcell Co Ltd Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.
CN118591619A (zh) 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
EP4497822A1 (en) 2022-03-23 2025-01-29 Kyoto University Method for producing regulatory t cells
IL315122A (en) 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
EP4556555A1 (en) 2022-07-14 2025-05-21 Orizuru Therapeutics, Inc. Fibrin gel sheet for cell transplantation
CN120112629A (zh) 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
WO2024071039A1 (ja) 2022-09-26 2024-04-04 レグセル株式会社 キメラ抗原受容体(car)を含む誘導性制御性t細胞
KR20250140618A (ko) 2023-02-08 2025-09-25 레그셀 가부시키가이샤 천포창을 치료 또는 예방하기 위한 의약 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
SI20324A (sl) * 1997-10-27 2001-02-28 Agouron Pharmaceuticals, Inc. Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
EP1615636A1 (en) * 2003-04-10 2006-01-18 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2015506376A5 (enExample)
JP2016508134A5 (enExample)
JP2015523397A5 (enExample)
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2016501221A5 (enExample)
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
JP2010525056A5 (enExample)
RU2018108589A (ru) Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2013506674A5 (enExample)
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
JP2016522254A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2017531673A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2019505529A5 (enExample)
JP2019501879A5 (enExample)
RU2014139955A (ru) Прокаспазная комбинированная терапия при глиобластоме
JP2017526662A (ja) 多発性骨髄腫を治療するための薬物の組み合わせ
JP2015522018A5 (enExample)
JP2013544892A5 (enExample)
JP2011046708A5 (enExample)
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
RU2014128387A (ru) Ингибиторы рi3к для лечения фиброзных заболеваний